Kidney Transplant Clinical Trials
Here are the 6 most popular medical studies for kidney transplant
Monoclonal Antibodies
Clazakizumab for Kidney Transplant Rejection
This trial is testing a new drug to treat people with antibody mediated rejection, which is a serious form of allograft rejection. Clazakizumab, an anti-IL6 monoclonal antibody, will be given monthly for six to twelve doses, and patients will have biopsies at 6 and 12 months to check for improvement.
Bone Marrow Aspirations for Kidney Transplant
This trial is testing whether two different tests can show why patients who have had a kidney transplant and have developed antibodies against their donor are at a greater risk for their transplanted organ being rejected.
Popular filter options for kidney transplant trials
Chronic Kidney Disease Clinical Trials
View 24 Chronic Kidney Disease medical studies.
Stem Cell Therapy
Immunological Tolerance for Kidney Transplants
This trial will study whether patients with a kidney transplant from a HLA-identical living donor can stop taking immunosuppressive drugs without damaging the transplanted kidney, by receiving hematopoietic stem cells from the same donor.
Monoclonal Antibodies
Desensitization Therapy for Kidney Disease
This trial is testing two drugs, REGN5459 and REGN5458, to see if they are safe and tolerable for patients with chronic kidney disease who need a kidney transplant and are highly sensitized to human leukocyte antigen. The secondary objectives are to determine the drug's effect on reducing levels of anti-HLA alloantibodies, on the duration of this effect, and on other immunological measures.
CAR T-cell Therapy
CAR-T Cell Therapy for Kidney Transplantation
This trial tests a new product, CART BCMA + huCART-19, to reduce cPRA in people who have been waiting for a kidney transplant for at least a year and have an immune system that would reject 99.5% of available kidneys. It will test safety & feasibility over a two-year period & followed up to 15 years.
Chronic Kidney Failure Clinical Trials
View 22 Chronic Kidney Failure medical studies.
Monoclonal Antibodies
Desensitization Therapy for Kidney Disease
This trial is testing two drugs, REGN5459 and REGN5458, to see if they are safe and tolerable for patients with chronic kidney disease who need a kidney transplant and are highly sensitized to human leukocyte antigen. The secondary objectives are to determine the drug's effect on reducing levels of anti-HLA alloantibodies, on the duration of this effect, and on other immunological measures.
CAR T-cell Therapy
CAR-T Cell Therapy for Kidney Transplantation
This trial tests a new product, CART BCMA + huCART-19, to reduce cPRA in people who have been waiting for a kidney transplant for at least a year and have an immune system that would reject 99.5% of available kidneys. It will test safety & feasibility over a two-year period & followed up to 15 years.
Immunosuppressant
Fingolimod for Kidney Transplantation
This trial is testing if a drug called fingolimod can help prevent kidney transplant failure. The study is double-blind, meaning neither the patients nor the doctors will know who is receiving the real drug or the fake drug (placebo).
HLA Positive Clinical Trials
View 8 HLA positive medical studies.
Hematopoietic Stem Cell Transplantation
Blood Stem Transplantation for Immune Tolerance
This trial will test if patients with a functioning kidney transplant and a matching donor can discontinue immunosuppressive drugs while maintaining normal renal function.
Phase 3 Kidney Transplant Clinical Trials
View 99 phase 3 kidney transplant medical studies.
Virus Therapy
Janssen Ad26.CoV2.S Vaccine for Kidney Transplant Recipients
This trial is testing if one dose of the Janssen vaccine can provide enough immunity for people who have had kidney transplants and have already received two or three doses of another vaccine.
SGLT2 Inhibitor
Dapagliflozin for Type 2 Diabetes in Kidney Transplant Recipients
This trial will compare the SGLT2 inhibitor dapagliflozin to placebo in 52 kidney transplant recipients with diabetes. The primary outcome is to determine if dapagliflozin is superior to placebo in reduction of blood pressure in KTR.
Kidney Transplant Clinical Trials With No Placebo
View 99 kidney transplant medical studies that do not have a placebo group.
Stem Cell Therapy
Immunological Tolerance for Kidney Transplants
This trial will study whether patients with a kidney transplant from a HLA-identical living donor can stop taking immunosuppressive drugs without damaging the transplanted kidney, by receiving hematopoietic stem cells from the same donor.
Virus Therapy
Janssen Ad26.CoV2.S Vaccine for Kidney Transplant Recipients
This trial is testing if one dose of the Janssen vaccine can provide enough immunity for people who have had kidney transplants and have already received two or three doses of another vaccine.
Monoclonal Antibodies
Desensitization Therapy for Kidney Disease
This trial is testing two drugs, REGN5459 and REGN5458, to see if they are safe and tolerable for patients with chronic kidney disease who need a kidney transplant and are highly sensitized to human leukocyte antigen. The secondary objectives are to determine the drug's effect on reducing levels of anti-HLA alloantibodies, on the duration of this effect, and on other immunological measures.
Calcineurin Inhibitor
Extended-release Tacrolimus vs Immediate-release Tacrolimus for Kidney Transplant Rejection
This trial will compare outcomes of kidney transplant patients taking Envarsus XR versus tacrolimus. Outcomes include rejection rates, HLA antibodies, kidney function, and cell-free DNA levels.
Calcineurin Inhibitor
Tacrolimus Extended-Release vs Immediate Release Tacrolimus for Kidney Transplant Recipients
This trial is testing whether a once-daily tacrolimus pill causes fewer side effects and is more convenient than the twice-daily tacrolimus pill, and whether patients' quality of life is better on the once-daily pill.
Hematopoietic Stem Cell Transplantation
Stem Cell Transplantation and Tregs Therapy for Kidney Transplant
This trial will test whether a combination of radiation and drugs followed by infusion of donor cells will allow recipients to eventually stop taking anti-rejection drugs after receiving a kidney from a living donor.
View More Kidney Transplant Trials
See another 70 many medical studies focused on kidney transplant.
Frequently Asked Questions
Introduction to kidney transplant
What are the top hospitals conducting kidney transplant research?
When it comes to cutting-edge clinical trials in the field of kidney transplant, several hospitals are leading the way. In Rochester, Minnesota, Mayo Clinic is at the forefront with six active kidney transplant trials. With its extensive expertise and state-of-the-art facilities, Mayo Clinic continues to push boundaries in this specialized area of medicine. Meanwhile, on the West Coast in Los Angeles, Cedars-Sinai Medical Center is also making significant contributions with four ongoing kidney transplant trials. This renowned institution has a long-standing reputation for excellence and innovation in healthcare. Further south in Charleston, South Carolinay transplant trials. With its extensive expertise and state-of-the-art facilities, Mayo Clinic continues to push boundaries in this specialized area of medicine. Meanwhile, on the West Coast in Los Angeles, Cedars-Sinai Medical Center is also making significant contributions with four ongoing kidney transplant trials. This renowned institution has a long-standing reputation for excellence and innovation in healthcare. Further south in Charleston, South Carolina, the Medical University of South Carolina is actively involved in four kidney transplant trials as well—showcasing their commitment to advancing transplantation techniques and improving patient outcomes.
Heading back north to Chicago brings us to the University of Illinois at Chicago—a hub for medical research and discovery. Here they have three active kidney transplant clinical trials underway that aim to explore novel treatment approaches and enhance post-transplant care protocols. Lastly but certainly not least—in sunny San Diego—the California Institute of Renal Research joins this esteemed group with three ongoing kidney transplant trials offering hope for patients awaiting life-changing transplants.
While these hospitals may not have conducted any previous specific clinical studies focused solely on kidney transplants according to available records; their current endeavors demonstrate a shared dedication towards advancing knowledge and refining methods surrounding this life-saving procedure. As we look toward the future of organ transplantation research, these institutions continue pushing boundaries as pioneers within their respective regions - bringing together experts from various disciplines who relentlessly work towards improving quality of life for those affected by renal failure
Which are the best cities for kidney transplant clinical trials?
In the realm of kidney transplant clinical trials, several cities emerge as frontrunners for cutting-edge research. Los Angeles, California leads the way with 15 active trials investigating treatments like Clazakizumab, Nested RCT - Treatment Group (Abatacept), and Anti-BK polyomavirus (AntiBKV). Chicago, Illinois closely follows with 13 ongoing studies focusing on interventions such as Clazakizumab, HIV D+/R+, and REGN5459. Additionally, New York City in New York and Philadelphia in Pennsylvania each host 11 active trials exploring similar avenues of treatment. Finally, Baltimore in Maryland rounds out the list with 10 ongoing trials centered around promising approaches like HIV D+/R+ and Clazakizumab. These cities serve as beacons of hope for individuals seeking access to advanced kidney transplant clinical trials that may revolutionize care options and improve outcomes.
Which are the top treatments for kidney transplant being explored in clinical trials?
Kidney transplant research is constantly evolving, and clinical trials are focusing on innovative treatments to improve outcomes. Currently, the top treatments being explored in clinical trials include:
- Belatacept: 8 active kidney transplant trials, 85 all-time kidney transplant trials
- Eculizumab: 6 active kidney transplant trials, 68 all-time kidney transplant trials
What are the most recent clinical trials for kidney transplant?
Exciting advancements in kidney transplant research are underway, offering new hope for patients in need. One such trial is exploring the potential of dapagliflozin—a medication typically used to treat diabetes—in improving outcomes after kidney transplantation. Additionally, researchers are investigating an innovative approach aimed at enhancing immune tolerance among mismatched kidney transplantt diabetes—in improving outcomes after kidney transplantation. Additionally, researchers are investigating an innovative approach aimed at enhancing immune tolerance among mismatched kidney transplant recipients. Another study focuses on the use of abatacept as a treatment option for these individuals. With ongoing efforts and rigorous trials, the field of kidney transplantation continues to evolve, bringing us closer to improved patient care and better long-term outcomes.
What kidney transplant clinical trials were recently completed?
Recently, several clinical trials focused on kidney transplant have achieved their objectives, bringing hope for improved treatments. Notably, a trial investigating the efficacy of Uproleselan in preventing kidney transplant rejection was completed in October 2021. Additionally, a study evaluating the use of mRNA-1273 as an innovative therapy for post-transplant complications reached its conclusion in September 2021. These advancements highlight the dedication of researchers and offer potential avenues to enhance outcomes for individuals undergoing kidney transplantation.